Please check your internet connection and try again.
# Hepa-Merz (L-Ornithine–L-Aspartate; LOLA)
## Overview
L-Ornithine–L-aspartate is an ammonia-lowering agent used as an adjunct in liver disease. It promotes ammonia detoxification through hepatic urea synthesis and extrahepatic glutamine synthesis.
Available formulations and strengths vary by country, commonly:
- **Oral granules:** usually 3 g LOLA per sachet
- **IV concentrate:** commonly 5 g/10 mL ampoule
It does **not replace standard treatment** for overt hepatic encephalopathy, such as lactulose and, when appropriate, rifaximin.
## Primary Indications
- Hyperammonemia associated with chronic liver disease
- Minimal or overt hepatic encephalopathy, as an adjunct when clinically appropriate
- Other uses may be locally approved; verify the product label and institutional protocol
## Adult Dosing
### Oral
Common labeled regimen:
- **3–6 g orally three times daily**, usually after meals
- If using 3-g sachets: **1–2 sachets three times daily**
- **Maximum commonly used dose: 18 g/day**
Dissolve granules in water or another approved beverage. Exact dosing depends on product strength and local labeling.
### Intravenous
For commonly available **5 g/10 mL ampoules**:
- Usual dose: **5–20 g/day IV**
- Equivalent to **1–4 ampoules/day**
- Severe hepatic encephalopathy or precoma/coma: doses up to **40 g/24 hours** may be used under specialist/institutional protocol
- Equivalent to **8 ampoules/24 hours**
- **Maximum infusion rate: 5 g/hour**
- Dilute and administer according to the product label; avoid rapid IV administration.
IV treatment is generally reserved for patients unable to take oral therapy or with severe disease.
## Pediatric Dosing
- **No well-established, universally accepted pediatric dose.**
- Safety and efficacy data are limited, particularly in young children.
- Use only with pediatric hepatology/critical-care consultation and a local protocol. Do not extrapolate adult maximum doses.
## Dose Adjustments
### Renal impairment
- **Contraindicated or not recommended in severe renal impairment**, commonly defined in product information as serum creatinine **>3 mg/dL (approximately >265 micromol/L)**.
- Avoid or seek specialist guidance in acute kidney injury, oliguria, or dialysis unless specifically directed by a hepatology/critical-care team.
- Monitor renal function during therapy.
### Hepatic impairment
- No routine dose reduction is generally specified for hepatic impairment; the drug is primarily used in this population.
- Dose and route should be guided by encephalopathy severity, ammonia trajectory, clinical response, and local protocol.
### Older adults
- No routine age-based adjustment, but assess renal function and frailty before treatment.
## Contraindications
- Hypersensitivity to L-ornithine, L-aspartate, or any formulation excipient
- Severe renal impairment, including markedly elevated serum creatinine per local labeling
- Product-specific contraindications, such as hereditary fructose intolerance or excipient intolerance, when applicable to oral formulations
- Avoid IV use when safe dilution, infusion monitoring, or renal assessment is not available
## Adverse Effects
Common or clinically important effects include:
- Nausea
- Vomiting
- Abdominal discomfort, diarrhea, or other gastrointestinal symptoms
- Headache or dizziness
- Injection-site irritation or phlebitis with IV administration
- Rare hypersensitivity reactions
Excessive dosing or rapid IV administration may increase gastrointestinal intolerance and other infusion-related effects. Stop treatment and provide urgent care for anaphylaxis, severe rash, bronchospasm, or cardiovascular instability.
## Key Drug Interactions
- No major, consistently established pharmacokinetic interactions are generally expected.
- Do not mix in the same syringe or infusion line with other medications unless compatibility is confirmed.
- Continue to assess for interactions from the overall hepatic encephalopathy regimen, particularly sedatives, opioids, alcohol, and other CNS depressants, which may worsen mental status.
- LOLA should not delay or replace treatment of precipitating factors or standard ammonia-lowering therapy.
## Monitoring
- Mental status and hepatic encephalopathy grade
- Ammonia concentration when clinically useful; interpret alongside clinical status
- Renal function: serum creatinine, eGFR, urine output
- Electrolytes and acid–base status, especially in critically ill patients
- Nausea, vomiting, diarrhea, hydration, and infusion-site reactions
- Liver function and assessment for precipitants of encephalopathy, such as infection, gastrointestinal bleeding, constipation, dehydration, renal failure, or sedative exposure
- Clinical response should be reassessed regularly; discontinue or modify therapy if there is no meaningful benefit or if toxicity occurs
## Clinical Pearls
- LOLA is an **adjunctive therapy**; standard treatment for overt hepatic encephalopathy remains essential.
- Oral therapy is preferred when the patient can safely swallow and absorb medications.
- For severe encephalopathy, use IV dosing only with specialist oversight and close monitoring.
- Verify the **sachet or ampoule strength**, as formulations differ internationally.
- Do not exceed the commonly labeled IV maximum of **40 g/24 hours** or infusion rate of **5 g/hour** without a specialist-approved protocol.
- Severe renal dysfunction is a major safety limitation.
- Ammonia levels alone should not determine treatment response; neurological status and precipitant control are more clinically important.
> **Educational disclaimer:** This summary is for educational use and does not replace individualized clinical judgment. Verify the current local prescribing information, formulation strength, renal restrictions, preparation instructions, and institutional hepatic encephalopathy protocol before prescribing or administering Hepa-Merz.
